Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification

Shang Chih Liao, Cheng Chieh Hung, Chien Te Lee, Chih Hsiung Lee, Chin Chan Lee, Chun Liang Lin, Chiao Yin Sun, Ben Chung Cheng, Chih Chao Yang, Chien Hsing Wu, Jin Bor Chen*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

3 Scopus citations

Abstract

This multicenter study was designed to assess the hemoglobin (Hb) stability and conversion ratio of the switch from epoetin beta to darbepoetin alfa in Taiwanese hemodialysis (HD) patients. A total of 135 HD patients were enrolled and randomized with intravenous darbepoetin alfa or epoetin beta. The study duration was 24 weeks. Equivalent doses and conversion ratios were assessed with respect to Hb stratification: low Hb (≥8.0 g/dL to ≤10.0 g/dL) and high Hb (>10.0 g/dL to ≤11.0 g/dL). The results showed stable Hb levels in the study period. At week 24, the conversion ratio was higher for high Hb than low Hb (296.4 IU/dose epoetin beta: 1 µg/dose darbepoetin alfa. vs. 277.2 IU/dose epoetin beta: 1 µg/dose darbepoetin alfa). In conclusion, the conversion ratio in the present study was higher than 1 µg: 200 IU for darbepoetin alfa: epoetin for treating anemia in Taiwanese HD patients.

Original languageEnglish
Pages (from-to)400-407
Number of pages8
JournalTherapeutic Apheresis and Dialysis
Volume20
Issue number4
DOIs
StatePublished - 01 08 2016

Bibliographical note

Publisher Copyright:
© 2016 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy

Keywords

  • Anemia
  • Darbepoetin alfa
  • Epoetin beta
  • Hemodialysis

Fingerprint

Dive into the research topics of 'Switch From Epoetin Beta to Darbepoetin Alfa Treatment of Anemia in Taiwanese Hemodialysis Patients: Dose Equivalence by Hemoglobin Stratification'. Together they form a unique fingerprint.

Cite this